SITE002-0180

SITE002 (USA) › SITE002-0180

SITE002-0180

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2026-04-07

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 1 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2023-01-19 (study day 100); relationship: not assessed

mild assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-15 (study day 4); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.